The relationship between circulating VEGF level and outcome of advanced Chinese NSCLC treated with gefitinib

19074 Background: VEGF represents a novel molecular target in NSCLC. We aimed to evaluate the association between VEGF plasma concentration, and response, overall survival of Chinese NSCLC patients treated with orally gefitinib (250 mg). Methods: Twenty patients’ blood samples were obtained from Chinese registration trial of gefitinib in NSCLC. Plasma VEGF before treatment (D0) and after treatment on D7, D14 was measured using a commercially available VEGF enzyme-linked immunosorbent assay kit (Quantikine human VEGF, R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. One-Way ANOVA, Kaplan-Meier method and Cox Regression were used in the statistical analysis. Results: Averaged plasma VEGF concentration on baseline (D0) and D7 and D14 were 92.68 ± 11.91 pg/mL, 112.36 ± 19.12 pg/mL and 159.14 ± 59.71 pg/mL respectively (P=0.406). VEGF concentration on D0 for the patients with CR+PR, SD, and PD were 124.55 pg/mL, 90.18 pg/mL and 74.32 pg/mL respectively (P=0.226) and changed to 66.36 ...